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Abstract
Background: A small percentage of children with Henoch-Schönlein purpura (HSP) develop a chronic form of the
disease that often requires prolonged corticosteroid therapy. Disease modifying anti-rheumatic agents (DMARDs) or
biologics have been successfully used to treat those refractory cases. Azathioprine is a DMARD that has been
reported to be effective in HSP nephritis and in adult cutaneous leukocytoclastic vasculitis, a condition with
cutaneous histology similar to HSP.
Case presentation: A description of 6 cases with relapsing HSP without significant renal involvement, treated with
azathioprine are reported. All 6 cases met the classification criteria for the diagnosis of HSP, had relapsing symptoms
despite corticosteroid use, were successfully treated with azathioprine and were tapered off of corticosteroids. The
duration of azathioprine therapy ranged from 7–21 months and no adverse events were reported.
Conclusions: Azathioprine is effective in controlling prolonged relapsing symptoms of HSP, allowing earlier
discontinuation of corticosteroids. This report shows that azathioprine can be included in the therapeutic options
for relapsing HSP and is the first case series in the literature of azathioprine use in HSP without significant renal
involvement.
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Background
Henoch-Schönlein purpura (HSP) is the most common
form of systemic vasculitis in children. The peak inci-
dence is 3 to 10 years of age. The disease is character-
ized by the tetrad of palpable purpura, arthritis/
arthralgia, abdominal pain, and renal manifestations.
Most cases recover spontaneously, and care is usually
supportive, including bed rest, hydration, and pain relief
with nonsteroidal anti-inflammatory drugs (NSAIDs) or
acetaminophen [1]. Although corticosteroid use is con-
troversial, it may result in accelerated resolution of
symptoms; however, long-term use is usually limited due
to adverse events [2]. Rarely, a subset of these patients
has persistent rash, arthritis or abdominal involvement
despite treatment with glucocorticoids or has recurrent
disease during glucocorticoid tapering. There is a paucity
of literature regarding therapy of such recalcitrant pa-
tients without renal involvement, although there are a
handful of case reports using methotrexate, mycopheno-
late mofetil, rituximab, azathioprine, colchicine and dap-
sone [3–11]. In this case series, we report the successful
use of azathioprine as a disease modulator in 6 patients
(Table 1) with recalcitrant disease, without significant
renal involvement, from two academic medical centers.
Case presentation
Patient 1 is a 7-year-old Caucasian female with HSP who
initially presented with a rash on her lower and upper
extremities. She was treated with 5 days of steroids.
Three weeks later, she developed non-bloody emesis
with a relapse of the rash on her face, upper and lower
extremities and torso, leading to treatment with 1 mg/
kg/day of prednisone. Three days later, she developed
drainage of her lower extremity lesions and hematem-
esis. She was admitted and treated with IV
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Table 1 Six patients with Henoch-Schönlein purpura treated with azathioprine
Demographics Clinical manifestations Duration of disease prior to
starting azathioprine
Azathioprine dose and duration Glucocorticoid dose and duration Length of remission
off all medication
Patient 1 7 y/o female Rash, abdominal pain 5 weeks 1 mg/kg/day for 11 months Discharged on methylprednisolone 1
mg/kg/day tapered over 6 weeks
(total of 9 weeks including
3 weeks of inpatient treatment)
15 months
Patient 2 11 y/o female Rash, arthralgias,
abdominal pain
7 months 1 mg/kg/day for 7 months Prednisone 0.5 mg/kg/day and taper
over 6 weeks
8 months
Patient 3 8 y/o female Rash, arthralgias 5 months 1 mg/kg/day for 13 months Prednisone 0.5 mg/kg/day and taper
over 6 weeks
4 years
Patient 4 9 y/o male Rash, arthralgias,
abdominal pain
3 months 2 mg/kg/day for 18 months
(still active and off steroids for
last 6 months)
Prednisone 1 mg/kg/day and taper over
14 months
N/A
Patient 5 9 y/o male Rash, abdominal pain,
renal disease
Intermittent disease over 4 years 1 mg/kg/day for 21 months Prednisone 0.5 mg/kg/day and taper
over 16 months
3.5 years
Patient 6 8 y/o female Rash, arthralgias,
abdominal pain













methylprednisolone 2 mg/kg/day and IV fluids. On the
fourth hospital day, she developed bloody stool after a
few days of intermittent abdominal pain. An abdominal
ultrasound showed small bowel intussusception, which
was reduced with an air contrast enema. During her
21 days of hospitalization, she intermittently had abdom-
inal pain and emesis after solid food re-introduction. Re-
peated attempts to taper oral glucocorticoids resulted in
the relapse of her symptoms, leading to the use of IV
methylprednisolone 1 mg/kg/day through a PICC. She
received one dose of intravenous immunoglobulin
(IVIG) 2 g/kg and was started on azathioprine 2 mg/kg/
day as long-term maintanance therapy. Her laboratory
evaluation was remarkable for an anti-nuclear antigen
(ANA) of 1:2560 titer with negative anti-neutrophil cyto-
plasmic antibody (ANCA), anti-double stranded DNA
(dsDNA), and extractable nuclear antigens (ENA). She
had normal hemoglobin (Hb) 13.5 g/L, complement
levels, and creatinine (Cr) 0.4 mg/dl and no proteinuria
or hematuria. Skin biopsy was not obtained. Her symp-
toms gradually improved and she was discharged on a
methylprednisolone taper that was discontinued 6 weeks
after discharge. Her rash and mild abdominal symptoms
persisted for 3 months post-discharge. She was contin-
ued on azathioprine for a total of 11 months, and
15 months after medication discontinuation, she
remained asymptomatic with unremarkable continuous
laboratory screening for an alternative diagnosis, such as
systemic lupus erythematosus (SLE).
Patient 2 is an 11-year-old Caucasian female who pre-
sented with palpable purpura, abdominal pain, and arth-
ritis. She was initially treated with NSAIDs. Over the
following 3 weeks, she developed multiple recurrences of
her rash affecting her upper and lower extremities and
lower abdomen, as well as a painful lesion of her right sole
that prevented her from walking. She was admitted and
received 2 days of IV methylprednisolone 5 mg/kg q6 h
for 5 doses. Due to the prolonged duration and severity of
her rash, she was discharged on a prednisone taper of
0.5 mg/kg/day over 6 weeks, and started on methotrexate
of 10 mg/m2 BSA. Skin biopsy was not obtained. Six
months later, methotrexate was switched to azathioprine
1 mg/kg/day due to recurrent purpura. Her symptoms
subsided, and within 2 months, control of her rash was
achieved. Azathioprine was discontinued after 7 months,
after which she remained asymptomatic without a rash.
Laboratory testing revealed negative ANCA, sedimenta-
tion rate (ESR) of 18 mm/h, C-reactive protein (CRP) of
1.9 mg/L, Cr 0.5 mg/dl, Hb 12 g/dl, and an unremarkable
urinalysis.
Patient 3 is an 8-year-old Caucasian female who pre-
sented with a purpuric rash of her lower extremities and
arthritis of her ankles. Her symptoms subsided without
the use of steroids, but she had persistent arthralgias.
Four months after the initial episode, following a febrile
illness, she developed a recurrence of her characteristic
rash and worsening joint symptoms. She was started on
a prednisone taper from an initial dose of 0.5 mg/kg/day
but had recurrence of her joint symptoms during taper-
ing. Her prednisone dose was increased to the initial
dose of 0.5 mg/kg/day, and azathioprine 1 mg/kg/day
was added. She discontinued prednisone 6 weeks later
and continued to be asymptomatic, with the exception
of a single episode of a breakthrough rash 4 months
later which resolved with a 5 day course of prednisone.
Over the following several months, she remained asymp-
tomatic and azathioprine was discontinued 7 months
after her last relapse, for a total of 13 months in total of
azathioprine treatment. Laboratory testing revealed
negative ANA, Hb 11 g/dl, ESR 9 mm/h, Cr 0.4 mg/dl,
and no proteinuria or hematuria. Skin biopsy was not
thought necessary to confirm the diagnosis.
Patient 4 is a 9-year-old Caucasian male diagnosed
with HSP six weeks prior to presentation. He initially
had partial improvement on prednisone 1 mg/kg/day
but then developed worsening symptoms with his pred-
nisone wean. His palpable purpuric rash was most
prominent on his bilateral distal lower extremities but
was also present mildly on his buttocks, abdomen, and
arms. He complained of arthralgias, testicular pain, and
mild abdominal pain with normal bowel movements
without hematochezia, mucous or signs of intussuscep-
tion. Prednisone was increased back to 1 mg/kg/day with
improvement of symptoms. A second but slower pred-
nisone taper resulted in the return/worsening of symp-
toms again at 0.5 mg/kg/day. Azathioprine was added
3 months after disease onset, with successful tapering off
of prednisone and no return of symptoms for the last
6 months. Laboratory evaluation showed ESR 11, CRP
0.8 mg/dL, urinalysis without proteinuria or hematuria,
Cr 0.44 mg/dl, Hb 13.5 g/dL, normal immunoglobulin A
(IgA), normal complement levels, and negative ANA,
anti-SSA, anti-SSB, ANCA, rheumatoid factor (RF), and
anti-cyclic citrullinated peptide (CCP) antibodies. Skin
biopsy was not obtained.
Patient 5 is a 9 year old Asian male with recurrent
HSP over 4 years with manifestations of palpable purpura,
abdominal pain with hematochezia but without intussus-
ception, intermittent mild hematuria and proteinuria, and
testicular pain with swelling. Laboratory evaluation was
remarkable for ESR 23, CRP 8.3 mg/L, urinalysis without
proteinuria but with brief intermittent hematuria, Cr 0.4,
Hb 13.4 g/dL, normal IgA and complement levels, and
negative ANA and ANCA antibodies. Skin biopsy was
suggestive of leucocytoclastic vasculitis with IgA depos-
ition typical of HSP. Renal biopsy was not performed.
Azathioprine 1 mg/kg/day was added to prednisone
0.5 mg/kg/day due to the recurrent nature of his
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symptoms and the lack of a sustained response to
glucocorticoids. The addition of azathioprine resulted
in dramatic improvement of all symptoms, and taper-
ing of prednisone was successful. Azathioprine was
used for 21 months total prior to discontinuation,
and the patient has currently sustained remission for
3.5 years off azathioprine and glucocorticoids.
Patient 6 is an 8-year-old Caucasian female with HSP
diagnosed 3 months prior to presentation, with manifes-
tations of palpable purpura, abdominal pain without
hematochezia or intussusception, and mild lower ex-
tremity arthralgias with morning stiffness. Laboratory
evaluation was remarkable for ESR 4, CRP 1.4 mg/L,
urinalysis without proteinuria or hematuria, Cr 0.5, Hb
12.3 g/dL, normal IgA and complement levels, and nega-
tive ANA and ANCA antibodies. Skin biopsy was not
obtained. Her symptoms were responsive to prednisone
0.5 mg/kg/day, but due to recurrence of symptoms dur-
ing the glucocorticoid taper, azathioprine 1 mg/kg/day
was added with rapid amelioration her symptoms. This
allowed successful tapering off of prednisone. Azathio-
prine was used for 13 months prior to discontinuation,
and the patient has sustained remission for 20 months
off azathioprine and glucocorticoids.
Conclusions
In this case series, we describe 6 patients meeting the
classification criteria for HSP [12], who developed pro-
longed and relapsing symptoms and were successfully
treated with azathioprine. None of these patients had
classic renal involvement. The duration of treatment
with azathioprine ranged from 7 to 21 months without a
relapse of disease after discontinuing treatment.
The course of HSP is usually benign and self-limited,
with only 1/3 of patients having recurrent disease. Since
the disease is usually self-limited, typically no treatment
is warranted. In the absence of renal disease, the initial
episode usually lasts approximately 1 month [1]. Recur-
rence of disease occurs most commonly in patients with
nephritis or more severe symptoms at presentation [13].
Treatment with glucocorticoids offers quick symptom-
atic relief and shortens the severity and duration of
gastrointestinal, joint, and cutaneous symptoms [1, 14]
Steroids are often used successfully in patients with lim-
ited oral intake due to their abdominal symptoms, a
painful rash, or difficulty ambulating. [2]. However,
treatment with glucocorticoids is controversial, as they
do not appear to alter or improve the final outcome, includ-
ing renal disease [15]. There are currently no established
evidence-based recommendations for glucocorticoid use in
HSP, although they are often used in clinical practice.
Management options for recalcitrant disease that is
poorly responsive to steroids or is steroid-dependent
have not been defined, and only a few case series of
patients managed with other medications have been re-
ported [3–11]. Azathioprine has been used with corticoste-
roids or other agents in cases of HSP nephritis (Table 2).
Results were encouraging as this combination seemed to
improve the clinical course of the nephritis, but random-
ized controlled trials (RCTs) are needed [16–21]. Only one
case of hemorrhagic bullous cutaneous HSP successfully
treated with azathioprine has been reported in the litera-
ture [11]. In addition, azathioprine has been used in cases
of cutaneous leukocytoclastic vasculitis with IgA depos-
ition that histologically resembles HSP [22]. Expert opinion
favors the use of colchicine or dapsone as first line treat-
ment for cutaneous leucocytoclastic vasculitis [23–25].
Efficacy of those agents is questionable, as the recom-
mendations are based on case reports, while a random-
ized controlled trial failed to show efficacy of colchicine
[26]. Azathioprine is recommended as second line
treatment by most authors for the treatment of cutane-
ous leucocytoclastic vasculitis [23–25].
Toxicity to the GI tract (elevation of liver enzymes, an-
orexia, nausea, vomiting) and the theoretical increased
risk of malignancy are the main concerns of azathioprine
use. The idiosyncratic arrest of granulocyte maturation
and subsequent risk of infection may be reduced by
adjusting the dose of azathioprine based on the measure-
ment of thiopurine S-methyltranferase levels (TPMT),
whose genetic variation has been related to the observed
bone marrow toxicity [27]. No adverse events were re-
ported in this case series, and safety monitoring included
a complete blood count (CBC) and complete metabolic
panel (CMP) to evaluate for liver toxicity or blood cell
dyscrasias.
HSP is usually a clinical diagnosis, therefore, a skin bi-
opsy is rarely obtained and usually no laboratory testing
is necessary to establish a diagnosis [12, 28]. However,
chronic or recurrent HSP symptoms should always raise
concern for alternative causes of cutaneous small vessel
vasculitis, such as ANCA-associated vasculitis or SLE
[29, 30]. In addition, ulcerative colitis has been misdiag-
nosed as HSP [31], while Familial Mediterannean Fever
(FMF) is also in the differential diagnosis. Frequently
FMF patients develop HSP and a genetic association be-
tween FMF and HSP has been shown [32, 33]. Laboratory
tests such as ANA, anti-dsDNA or ANCA antibodies are
usually negative in HSP, and their positivity may be sug-
gestive of another diagnosis. In these cases, careful clinical
and laboratory diagnostic evaluation, including a skin bi-
opsy, is warranted [1]. In this series a skin biopsy was ob-
tained only in patient 5. In the other cases the appearance
of the rash, the concomitant symptoms and laboratory
testing were strongly supportive of a diagnosis of HSP,
making biopsy unnecessary.
While HSP is typically a self-limited disease, our cases
all demonstrated persistent or recurrent symptoms. It is
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Table 2 Summary of studies and case reports identified by systemic literature search. We searched the Medline indexed literature after 1996 combining the words azathioprine,







Treatment used Duration of study Conclusions
Bergstein
(1998) [16]
21 Crescentic HSP nephritis Azathioprine and steroids 9–24 months and average follow
up time of 32 months
Azathioprine is effective in reducing hematuria,
proteinuria, serum creatinine and increasing




17 Severe HSP nephritis Azathioprine and prednisone Azathioprine 1–4 mg/kg and
prednisone for 46.7 +/− 19 weeks
compared to historical controls
treated in various ways
No progression of renal lesions after treatment




9 Severe HSP nephritis Azathioprine and steroids Azathioprine treatment of a mean of 14.7 months and
steroids for 12.1 months, 4.7 years mean follow up
Mean resolution of proteinuria and hematuria
6.5 and 6.6 months respectively
Shin (2005)
[19]
20 Severe HSP nephritis Azathioprine and steroids versus
steroids alone
Azathioprine for 8 months, steroids
median of 1.7 years, median follow
up 4.8 years
Azathioprine and steroids ameliorate
histopathological features and improve the
clinical course of severe HSP nephritis. No
significant differences in hematuria and
proteinuria between the groups.
Shenoy
(2007) [20]
27 HSP nephritis grade IIIb
or greater
Induction with steroids and CYC
for 8–12 weeks followed by
maintanance with azathioprine
and steroids
Azathioprine for a mean of 12 months,
6.9 y mean follow up period,
37 % complete recovery, 40.7 % persistent
proteinuria, 7.4 proteinuria and HTN, 14.8 %
ESKD. Poor outcome on those being older at
presentation and having crescents/heavy





Azathioprine 2.5 mg/kg with
steroids
Follow up 5 months Symptom resolution
Ninchoji
(2011) [21]
32 Moderate or severe HSP
nephritis
Azathioprine 2 mg/kg, steroids and
anticoagulants for modarate severe
and severe nephritis in comparison
to ACE-I or ARB for moderate severe
nephritis
Combination therapy including
azathioprine for 6 months
90 % resolution of moderate HSP nephritis by
14.9 months and 90 % resolution of severe
nephritis by 11.1 months











unlikely the resolution of symptoms in these patients
was simply due to the natural course of the disease and
was more likely due to the effects of azathioprine. Aza-
thioprine appeared to be an effective steroid-sparing
medication, allowing all steroid-dependent patients to be
successfully tapered off of steroids. No official guideline
is available for treatment duration, and this case series
does not establish the optimal duration of azathioprine
treatment. However, once symptoms are controlled, it ap-
pears that discontinuation of therapy may be attempted
empirically after complete disease remission has been
achieved for 6–15 months.
Our experience with the use of azathioprine has also
been favorable in 4 additional cases not reported here.
These include 2 cases with persistent skin and renal dis-
ease responding to treatment but without enough follow
up time, one case of relapsing skin disease responsive to
treatment with azathioprine but without significant follow
up time to be reported, and one patient with relapsing
skin disease and renal involvement in which azathioprine
successfully achieved remission. Only in one case with
persistent skin and renal involvement did azathioprine
1 mg/kg fail to achieve renal symptom control and was
discontinued within 2 months.
In summary, this case series demonstrates improved
symptom control, steroid-sparing effect, and induction
of remission with azathioprine in patients with recalcitrant
HSP without renal disease. No patient had any adverse
events associated with azathioprine therapy. Randomized
controlled trials comparing the different therapeutic op-
tions for these type of patients are needed in the future.
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